anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses compositions and formulations for the treatment of clean or infected wounds, some of the inventive formulations can be used to reduce or eliminate microbial contamination from surfaces such as skin, and inanimate objects such as countertops, cooking utensils, medical devices, cookware, food, grooming aids and agricultural biocides, and the like. Some of these compositions and formulations are well suited for use in wound dressings. Some of the formulation can kill and/or inhibit the growth of pathogenic bacteria, fungi, spores and viruses. The formulations comprise a compound such as an osmoticum in high enough concentration to create an osmotic gradient and at least one compound that acts to comprise the integrity of a microorganism's membrane or cell wall. These formulations may optimally include at least one agent that thickens the formulations. In some aspects the formulation is in the form of an emulsion.
The present disclosure relates to a method of measuring a calorie expenditure by a user. The method includes detecting a current blood flow through a section of a body of the user, during a physical activity. The method includes predicting a blood flow for a recovery period of the user after the completion of the physical activity, based on the current blood flow. The method includes determining a total blood flow through the section of the body of the user during the physical activity and the recovery period. A value of MET is determined based on the total blood flow. The method includes determining calories expenditure in real time by the user during the physical activity and the recovery period, based on the value of the MET and physical characteristics of the user.
Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = \[glomerular filtration rate + 25\] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.
With the lack of specific signs and symptoms, pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at late metastatic stages, resulting in poor survival outcomes. Among various biomarkers, microRNA-21 (miR-21), a small non-coding RNA, is highly expressed in PDAC. By inhibiting regulatory proteins at the 3' untranslated regions (UTR), miR-21 holds significant roles in PDAC cell proliferation, epithelial-mesenchymal transition, angiogenesis, as well as cancer invasion, metastasis, and resistance therapy. We conducted a systematic search across major databases for articles on miR-21 and pancreatic cancer mainly published within the last decade, focusing on their diagnostic, prognostic, therapeutic, and biological roles. This rigorous approach ensured a comprehensive review of miR-21's multifaceted role in pancreatic cancers. In this review, we explore the current understandings and future directions regarding the regulation, diagnostic, prognostic, and therapeutic potential of targeting miR-21 in PDAC. This exhaustive review discusses the involvement of miR-21 in proliferation, epithelial-mesenchymal transition (EMT), apoptosis modulation, angiogenesis, and its role in therapy resistance. Also discussed in the review is the interplay between various molecular pathways that contribute to tumor progression, with specific reference to pancreatic ductal adenocarcinoma.
PCT No. PCT/FR96/00480 Sec. 371 Date Dec. 3, 1997 Sec. 102(e) Date Dec. 3, 1997 PCT Filed Mar. 29, 1996 PCT Pub. No. WO96/30000 PCT Pub. Date Oct. 3, 1996The invention concerns a pharmaceutical composition for transdermal administration, characterized in that it comprises: a) optionally, a polymeric release matrix capable of forming a flexible film after drying, chosen from cellulose polymers or copolymers or vinylpyrrolidone/vinyl acetate copolymers b) an active principle c) a promoter of transcutaneous absorption of the active principle d) a physiologically acceptable non-aqueous solvent capable of dissolving the release matrix, the active principle and the transcutaneous absorption promoter and also capable of being rapidly removed by evaporation on contact with the skin.
Uterine leiomyomas are rare in the paediatric population. This report describes a rare case of a submucous leiomyoma in an adolescent girl. The patient presented with a history of abnormal and painful period which was refractory to medical treatment. Sonographic findings revealed a uterine mass that protruded through the cervix until the upper third of the vagina. A hysteroscopic resection was performed, and a pathological examination confirmed a leiomyoma. 12 months after surgery, there were no signs of recurrence. Conservative sparing-fertility management, such as hysteroscopic resection, is the best option with a type 0 submucosal fibroid, especially in adolescents and young women.
Triamcinolone acetonide dental paste may cause local adverse reactions. If irritation develops, triamcinolone acetonide dental paste should be discontinued and appropriate therapy instituted. Allergic contact sensitization with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.

If concomitant mucosal infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of triamcinolone acetonide dental paste should be discontinued until the infection has been adequately controlled.

If significant regeneration or repair of oral tissues has not occurred in seven days, additional investigation into the etiology of the oral lesion is advised.

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, glucosuria, and other adverse effects known to occur with parenterally-administered steroid preparations; therefore, it may be advisable to periodically evaluate patients on prolonged therapy with corticosteroid-containing dental pastes for evidence of HPA axis suppression (see PRECAUTIONS, Laboratory Tests). If HPA axis suppression is noted, an attempt should be made to withdraw the drug or to reduce the frequency of application. Recovery of HPA axis function is generally prompt and complete upon discontinuation of therapy.
The invention relates to a method of treating hyperostosis with traditional Chinese medicines. The method includes materials, decocting medicines and an eating manner. The method includes cleaning Chinese clematis root, pyrola herb and golden chicken fern, adding the Chinese clematis root, the pyrola herb and the golden chicken fern into an earthen pot, dicing skinless chicken breast, adding the diced skinless chicken breast into the pot, adding 10 bowls of water, decocting with fire until three bowls of medicine decoction is left, removing medicine dregs, and drinking the decoction when the decoction is warm. The decoction is drunk one time in the morning, one time at noon, and one time at night. One bowl of the decoction is drunk each time. A course comprises 10 days.
All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
Selective dorsal rhizotomy (SDR) is commonly used to permanently reduce spasticity in children with cerebral palsy (CP). However, studies have yielded varying results regarding muscle strength and activity after SDR. Some studies indicate weakness or no changes, while a recent study using NMSK simulations demonstrates improvements in muscle forces during walking. These findings suggest that SDR may alleviate spasticity, reducing dynamic muscle constraints and enhancing muscle force without altering muscle activity during walking in children with CP. In this study, we combined NMSK simulations with physical examinations to assess children with CP who underwent SDR, comparing them to well-matched peers who did not undergo the procedure. Each group (SDR and No-SDR) included 81 children, with pre- and post-SDR assessments. Both groups were well-matched in terms of demographics, clinical characteristics, and gait parameters. The results of the physical examination indicate that SDR significantly reduces spasticity without impacting muscle strength. Furthermore, our findings show no significant differences in gait deviation index improvements and walking speed between the two groups. Additionally, there were no statistically significant changes in muscle activity during walking before and after SDR for both groups. NMSK results demonstrate a significant increase in muscle force in the semimembranosus and calf muscles during walking, compared to children with CP who received other clinical treatments. Our findings confirm that although SDR does not significantly impact muscle strength compared to other treatments, it creates a more favorable dynamic environment for suboptimal muscle force production, which is essential for walking.
Anatomic simulators, assemblies, and related methods are disclosed. In some embodiments, an anatomic simulator may include constraint panels that define a variably sized volume configured to receive an organ model. An elastic member may be configured to provide a restorative force when the constraint panels are moved to an expanded configuration. Alignment apertures in the constraint panels may be configured to permit marking of an organ model and/or visibility of a mark disposed on the organ model to position and orient the organ model in the anatomic simulator. In some embodiments, an anatomic simulation assembly may include an anatomic simulator, a pressure source, pneumatic controls, a pressure sensor, and a processor. In some embodiments, a method of simulating anatomic motion may include flowing a fluid to an organ model, sensing a pressure, and controlling the flow of fluid based on the sensed pressure to maintain a target pressure.
A humanised antibody capable of binding to the MUC 1  mucin antigen comprises a light chain and a heavy chain. The variable region of the light chain (V L ) comprising an amino acid sequence which is substantially homologous with the sequence of  FIG. 1A  and the variable region of the heavy chain (V H ) comprising an amino acid sequence which is substantially homologous with the sequence of  FIG. 1B . The amino acid residue at position 46 on V L  is backmutated to arginine, and the amino acid residue at position 47 on V H  is backmutated to leucine. The humanised antibody has use in the diagnosis and/or treatment of cancer.
A hierarchical workflow is configured to associate examination information captured using an imaging platform with contextual metadata. The examination information may include ultrasound image data, which may be associated with annotations, measurements, pathology, body markers, and/or the like. The hierarchical workflow may comprise templates associated with respective anatomical regions, locations, volumes, and/or surfaces. A template may define configuration data to automatically adapt the imaging platform to capture imaging data in the corresponding anatomical region. The template may further include guidance information for the operator, including processing steps for capturing relevant examination information. Additional examination information may be captured and included in the hierarchical workflow.
Background and Objectives: The experience of unpleasant sensory phenomena after lower limb amputations (LLAs), including phantom limb pain (PLP), phantom limb sensation (PLS), and residual limb pain (RLP), impacts global healthcare and adversely affects outcomes post-amputation. This study aimed to describe the distribution of PLP, PLS, and RLP among patients with LLAs registered in the Heidelberg Amputation Registry. The primary objective was to determine the prevalence of sensory abnormalities across different amputation levels and causes. Materials and Methods: In this single-center, cross-sectional study, data from 459 patients registered in the Heidelberg Amputation Registry were analyzed for the occurrence of PLP, PLS and RLP. Subsequently, logistic regression models were used to identify the independent risk factors associated with sensory disturbances following LLAs. The mean age of the LLA patients (31% female, 69% male) was 58 years (SD ± 18). Results: The patients were, on average, 44 years old (SD ± 22) at the time of amputation, with a mean duration since amputation of 15 years (SD ± 17). Transtibial amputations were the most common (43%), followed by transfemoral (39%) and partial foot amputations (10%). Hip and knee disarticulations were observed in 3.7% and 3.5% of the cohort, respectively, with hemipelvectomies accounting for 1%. Traumatic injuries (32%) and neoplastic disorders (22%) were the leading causes of LLAs, while peripheral artery disease and diabetes were responsible for 12% and 6% of cases, respectively. Importantly, a significant proportion of participants (85%) reported experiencing abnormal sensations. The prevalence rates for phantom limb pain (PLP), phantom limb sensation (PLS), and residual limb pain (RLP) were 58%, 66%, and 46%, respectively. The occurrence of sensory disturbances, with the exception of RLP, was significantly affected by the level of amputation. Notably, the age at amputation emerged as an independent risk factor for developing abnormal sensations, including PLS. Conclusions: In conclusion, this study provides a comprehensive overview of sensory abnormalities in a diverse cohort of LLA patients, highlighting the age at amputation as an important factor. The findings emphasize the role of comprehensive registries in enhancing care for individuals with amputations and guiding targeted pain management strategies.
The standard of treatment for node-positive endometrial cancer (FIGO Stage IIIC) in North America has been systemic therapy with or without additional external beam radiation therapy (RT) given as pelvic or extended field RT. However, this treatment paradigm is rapidly evolving with improvements in systemic chemotherapy, the emergence of targeted therapies, and improved molecular characterization of these tumors. The biggest question facing providers regarding management of stage IIIC endometrial cancer at this time is: what is the best management strategy to use with regard to combinations of cytotoxic chemotherapy, immunotherapy, other targeted therapeutics, and radiation that will maximize clinical benefit and minimize toxicities for the best patient outcomes? While clinicians await the results of ongoing clinical trials regarding combined immunotherapy/RT as well as management based on molecular classification, we must make decisions regarding the best treatment combinations for our patients. Based on the available literature, we are offering stage IIIC patients without measurable disease postoperatively both adjuvant chemotherapy and IMRT with carboplatin, paclitaxel, and with or without pembrolizumab/dostarlimab as primary adjuvant therapy. Patients with measurable disease post operatively, high risk histologies, or stage IV disease receive chemoimmunotherapy, and vaginal brachytherapy is added for those with uterine risk factors for vaginal recurrence. In the setting of endometrioid EC recurrence more than 6 months after treatment, patients with pelvic nodal and vaginal recurrence are offered IMRT and brachytherapy without chemotherapy. For measurable recurrence not suitable for pelvic radiation alone, chemoimmunotherapy is preferred as standard of care.
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and namely to immunology. It can be used to make vaccines on the basis of a nucleic acid. The vaccine contains one or more mRNA polynucleotides having an open reading frame encoding an antigenic polypeptide, and the antigenic polypeptide is derived from a bacterial agent or a viral agent forming a cationic lipid nanoparticle that contains 40-60% of ionizable cationic lipids, 5-15% of neutral lipids, 25-40% of sterol and 0.5-15% of PEG-modified lipids. The group of inventions also relates to a vaccine containing one or more mRNA polynucleotides having an open reading frame encoding a hemagglutinin protein, and a pharmaceutically acceptable carrier or an excipient forming a cationic lipid nanoparticle containing 40-60% of ionizable cationic lipids, 5-15% of neutral lipids, 25-40% of sterol and 0.5-3% of PEG-modified lipids. The mRNA polynucleotide includes a chemical modification. The chemical modification includes N1-methylpsevdouridine or 5-methylcytosine.EFFECT: use of these lipid carriers in certain ratios makes it possible to efficiently deliver mRNA to a subject in vivo.69 cl, 28 ex, 49 tbl, 23 dwg
The invention provides a polypeptide specifically bound with MUC1 protein, a targeted drug-loading co-delivery system, and a preparation method and application thereof. The targeted drug-loaded co-delivery system comprises a targeted drug-loaded long-circulating liposome and a targeted drug-loaded micelle. The polypeptide specifically combined with MUC1 protein is prepared by a solid phase polypeptide synthesis method, and the general formula of the amino acid sequence of the polypeptide is X 1 ‑DR‑X 2 ‑VRTQFNQYDTRAASD‑X 3 ‑G‑X 4 ‑X 5 Wherein X is 1 Is amino terminal, X 5 Is carboxyl terminal. The targeted drug-loaded long-circulating liposome comprises phospholipid, cholesterol, amphiphilic polymer, polypeptide-amphiphilic polymer and drug active components. The targeted drug-loaded micelle comprises an amphiphilic polymer, a polypeptide-amphiphilic polymer and a drug active component. The polypeptide specifically combined with the MUC1 protein, the targeted drug-loaded long-circulating liposome and the targeted drug-loaded micelle can be used for preparing antitumor drugs.
According to the present invention, a self-produced customized skin gel pack can be customized in real-time by a purchase user. The self-produced customized skin gel pack comprises a base product. The base product includes: a base composition; and a base container part storing the base composition. The base composition contains a designated base component, is stored in a liquid state that can be mixed with a functional product, and is solidified under designated conditions to become a gel state which can be molded into a skin gel pack detachably attached to a designated skin area. In the base product, N (N>=1) functional compositions containing designated functional components are stored in designated N functional container parts. The base product includes a spare accommodation volume which is designated to be secured or securable in a volume range greater than or equal to the sum of the volumes of N functional compositions. Accordingly, a purchase user can put the N functional compositions stored in the N functional container parts corresponding to N functional products stored as much as the volume of the designated N functional compositions into the base container part and mix the N functional compositions with the base composition. According to the present invention, a user can produce a customized skin gel pack optimized for his or her current skin condition.
Depression during pregnancy is a common mental health problem. Pregnant women with depression often continue to feel depressed after their baby is born, which can have several negative effects for both mother and child. For example, depressed mothers can find it harder to build a good relationship with their baby. Existing treatments for depression may not be sufficient to also improve the relationship between mother and baby. Depressed mothers may therefore need more specific help with connecting to their baby.

One promising new intervention is Baby CHAT. Baby CHAT is a single-session group that helps expectant parents learn about their unborn baby by viewing moving 4D ultrasound scans. It is believed that this will help parents to build a stronger relationship with their unborn baby. Baby CHAT has already been trialled with parents without any mental health problems, with promising results. This study aims to assess whether Baby CHAT is helpful for pregnant women with depression, collect data to inform future large-scale trials, and to develop the intervention from participants' feedback. The main research question asks: is Baby CHAT acceptable and feasible to deliver with pregnant women with depression?

Participants eligible to take part in the project will be people aged ≥18 years who are pregnant, between 20- and 34-weeks' gestation, and currently experiencing depressive symptoms. The project is taking place at an NHS site, with participants recruited from mental health and maternity services and online advertising. Participants will attend an online Baby CHAT group and complete online questionnaires at three time points (before and after Baby CHAT, and at one-month follow-up). The questionnaires will assess participants' relationship with their unborn baby, their ability to imagine their unborn baby as a separate person, and their level of depressive symptoms. The anticipated study end date is May 2023.
Non-small-cell lung cancer (NSCLC) is the first leading cause of cancer death in the world. Systemic chemotherapy has contributed to the only choice for more than 50% NSCLC patients. The genetic abnormalities lead to different therapy response to the same chemotherapy scheme in NSCLC patients. At present, early assessment and prediction is the key for optimize NSCLC therapy. 18F-FDG PET/CT is a noninvasive cell metabolism reaction molecular imaging technology which can assess cancer glucose metabolism sensitively and react cancer proliferation to some degree. Hence 18F-FDG PET/CT may be used to assess NSCLC therapy response noninvasively. It is a reliable method to individualize NSCLC treatment clinically by define the appropriate metabolism response cut-off values and assess time points of 18F-FDG PET/CT in predicting different genetic NSCLC patients.The subject is going to use 18F-FDG PET/CT to assess different genetic NSCLC metabolism after cisplatin chemotherapy and targeted therapy, define the assessment criteria for the role of 18F-FDG PET/CT in NSCLC treatment respone and at last build multi-centre clinical trial platform of molecular classification and molecular imaging for cancer chemotherapy assessment.
A magnetic resonance examination system is disclosed that is provided with a graphical user interface and Jack Smith an (software) analysis module. The analysis module is configured to analyse examination information, notably a selected examination protocol, for actions to be taken by the operator, such connecting auxiliary equipment or radio frequency receiver coils to the magnetic resonance examination system. The analysis module supplies the actions to be taken to the (graphical) user interface at the proper instant before or during carrying-out the examination protocol. In Respiratory; this way the operator is guided and supported in the performance of the selected examination protocol. This improves the efficiency of workflow in performing one or more selected protocols. Preferably, the graphical user interface is provided inside the examination room and may be mounted on the gantry.